ReviewExperimental hematology & oncology2015
Novel antidotes for target specific oral anticoagulants.
Review in Experimental hematology & oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report.World journal of clinical cases · 2022Article
- An Appraisal of Antidotes' Effectiveness: Evidence of the Use of Phyto-Antidotes and Biotechnological Advancements.Molecules (Basel, Switzerland) · 2020Review
- New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Biomolecules & therapeutics · 2017Review
- The role of new oral anticoagulants in orthopaedics: an update of recent evidence.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2017Review
- [Vitamin K antagonists : Is their prescription really "medical malpractice" today?]Der Internist · 2017Review
- Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.European cardiology · 2016Review
- New Direct Oral Anticoagulants (DOAC) and Their Use Today.Dentistry journal · 2016Review
- Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Journal of hematology & oncology · 2016Article
- Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications.BMC oral health · 2016Article
- Evaluating the benefits of home-based management of atrial fibrillation: current perspectives.Pragmatic and observational research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.